Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer.
Journal: Nature communications
Published: July 03, 2024
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.
Journal: Science advances
Published: November 24, 2023
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors.
Journal: bioRxiv : the preprint server for biology
Published: February 13, 2023
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours.
Journal: British journal of cancer
Published: October 29, 2020
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 12, 2020
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.
Journal: The Lancet. Respiratory medicine
Published: March 11, 2019
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Journal: Molecular cancer therapeutics
Published: February 15, 2019
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.
Journal: JCO precision oncology
Published: August 21, 2018
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Journal: Molecular cancer therapeutics
Published: August 01, 2018
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 12, 2017
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.
Journal: Cancer discovery
Published: January 22, 2014
Last Updated: 09/26/2026